Opinion
Video
Author(s):
The panel reviews data from the SunRISe-1 trial investigating TAR-200 and offers its impressions on the efficacy and safety findings.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
Durvalumab plus BCG significantly improves DFS in NMIBC
Physical function and frailty measures offer distinct insights in patients with bladder cancer
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
Clarifying CPT 52353 billing for same-side stone cases